糖尿病肾病发病机制及药物研发进展

刘学武 ,  姜德建 ,  杜艳华

中国临床药理学与治疗学 ›› 2026, Vol. 31 ›› Issue (6) : 735 -751.

PDF (8133KB)
中国临床药理学与治疗学 ›› 2026, Vol. 31 ›› Issue (6) : 735 -751. DOI: 10.12092/j.issn.1009-2501.2026.06.003

糖尿病肾病发病机制及药物研发进展

作者信息 +

Progress in pathogenesis and drug development of diabetic kidney disease

Author information +
文章历史 +
PDF (8327K)

摘要

糖尿病肾病(diabetic kidney disease,DKD)是糖尿病主要的并发症之一,是一种微血管病变,临床表现为蛋白尿、估算肾小球滤过率(estimated glomerular filtration rate,eGFR)进行性下降,组织形态学改变则表现为系膜增生和基底膜增厚、肾小球硬化和纤维化,是导致终末期肾病(end stage renal disease,ESRD)的主要原因。DKD 的发病机制复杂,遗传因素、能量代谢异常、免疫和炎症、血流动力学异常等因素均参与并影响 DKD 的形成及疾病进展,且复杂分子机制也为 DKD 的模型构建和新药研发带来了极大的挑战,本文综述了近年来 DKD 在发病机制研究、动物疾病模型研究以及新药研发等方面的相关进展,旨在为治疗 DKD 药物开发提供新的思路。

Abstract

Diabetic kidney disease (DKD), a kind of microvascular lesion, is one of the major complications of diabetes. Clinically, it is characterized by proteinuria, mesangial proliferation and thickening of the basement membrane, glomerular sclerosis and fibrosis, and progressive decline of estimated glomerular filtration rate (eGFR), and is recognized as the main cause of end-stage renal disease (ESRD). The pathogenesis of DKD is complex, with genetic factors, abnormal energy metabolism, immunity and inflammation, and hemodynamic abnormalities all participating in and influencing the formation and progression of DKD. The complex molecular mechanism also brings great challenges to the construction of DKD models and the development of new drugs. This article reviews the recent progress in the research of the pathogenesis of DKD, animal disease models, and new drug development, aiming to provide new ideas for the development of drugs for the treatment of DKD.

关键词

糖尿病肾病 / 动物模型 / 药物评价

Key words

diabetic kidney disease / animal model / drug evaluation

引用本文

引用格式 ▾
刘学武,姜德建,杜艳华. 糖尿病肾病发病机制及药物研发进展[J]. 中国临床药理学与治疗学, 2026, 31(6): 735-751 DOI:10.12092/j.issn.1009-2501.2026.06.003

登录浏览全文

4963

注册一个新账户 忘记密码

参考文献

[1]

Owens DR, Gurudas S, Sivaprasad S, et al. IDF diabetes atlas: a worldwide review of studies utilizing retinal photography to screen for diabetic retinopathy from 2017 to 2024 inclusive[J].Diabetes Res Clin Pract, 2025, 226: 112346.

[2]

Wang Y, Zhang J, Zhao Y, et al. COL4A3 gene variants and diabetic kidney disease in mody[J].Clin J Am Soc Nephrol, 2018, 13(8): 1162-1171.

[3]

Al-Dabet MM, Shahzad K, Elwakiel A, et al. Reversal of the renal hyperglycemic memory in diabetic kidney disease by targeting sustained tubular p21 expression[J].Nat Commun, 2022, 13(1): 5062.

[4]

Lu L, Zhu M, Wu Q, et al. Sirt7/HIC1 complex participates in hyperglycaemia-mediated EndMT via modulation of SDC1 expression in diabetic kidney disease and metabolic memory[J].J Cell Mol Med, 2024, 28(9): e18336.

[5]

Xu Z, Jia K, Wang H, et al. METTL14-regulated PI3K/Akt signaling pathway via PTEN affects HDAC5-mediated epithelial-mesenchymal transition of renal tubular cells in diabetic kidney disease[J].Cell Death Dis, 2021, 12(1): 32.

[6]

Mattei AL, Bailly N, Meissner A.DNA methylation: a historical perspective[J].Trends Genet, 2022, 38(7): 676-707.

[7]

Hill C, Duffy S, Kettyle LM, et al. Differential methylation of telomere-related genes is associated with kidney disease in individuals with type 1 diabetes[J].Genes (Basel), 2023, 14(5): 1029.

[8]

Chen G, Chen H, Ren S, et al. Aberrant DNA methylation of mTOR pathway genes promotes inflammatory activation of immune cells in diabetic kidney disease[J].Kidney Int, 2019, 96(2): 409-420.

[9]

Jiang Q, Chen H, Wang K, et al. Circ_0054633 silencing suppresses hyperglycemia-induced extracellular matrix accumulation in renal mesangial cells by regulating MiR-136-5p/SMAD3 signaling[J].Noncoding RNA Res, 2025, 13: 84-93.

[10]

Feng X, Zhao J, Ding J, et al. LncRNA Blnc1 expression and its effect on renal fibrosis in diabetic nephropathy[J].Am J Transl Res, 2019, 11(9): 5664-5672.

[11]

Harvey SJ, Jarad G, Cunningham J, et al. Podocyte-specific deletion of dicer alters cytoskeletal dynamics and causes glomerular disease[J].J Am Soc Nephrol, 2008, 19(11): 2150-2158.

[12]

Liu J, Xiong Y, Mo H, et al. MicroRNA-29b plays a vital role in podocyte injury and glomerular diseases through inducing mitochondrial dysfunction[J].Int J Biol Sci, 2024, 20(12): 4654-4673.

[13]

Chen DT, Saltos AN, Rose T, et al. Early adverse event derived biomarkers in predicting clinical outcomes in patients with advanced non-small cell lung cancer treated with immunotherapy[J].Cancers (Basel), 2023, 15(9): 2521.

[14]

Haque T, Cadenas FL, Xicoy B, et al. Phase 1 study of JNJ-64619178, a protein arginine methyltransferase 5 inhibitor, in patients with lower-risk myelodysplastic syndromes[J].Leuk Res, 2023, 134: 107390.

[15]

To KK W, Tolu SS, Wang L, et al. HDAC inhibitors: cardiotoxicity and paradoxical cardioprotective effect in ischemia-reperfusion myocardiocyte injury[J].Semin Cancer Biol, 2025, 113: 25-38.

[16]

Li D, Hsu FC, Palmer ND, et al. Multiomics analyses identify akr1a1 as a biomarker for diabetic kidney disease[J].Diabetes, 2024, 73(7): 1188-1195.

[17]

Du Q, Fu YX, Shu AM, et al. Loganin alleviates macrophage infiltration and activation by inhibiting the MCP-1/CCR2 axis in diabetic nephropathy[J].Life Sci, 2021, 272: 118808.

[18]

Fumo P, Kuncio GS, Ziyadeh FN.PKC and high glucose stimulate collagen alpha 1 (IV) transcriptional activity in a reporter mesangial cell line[J].Am J Physiol, 1994, 267(4 Pt 2): F632-638.

[19]

Zuo F, Wang Y, Xu X, et al. CCDC92 deficiency ameliorates podocyte lipotoxicity in diabetic kidney disease[J].Metabolism, 2024, 150: 155724.

[20]

Zuo FW, Liu ZY, Wang MW, et al. CCDC92 promotes podocyte injury by regulating PA28α/ABCA1/cholesterol efflux axis in type 2 diabetic mice[J].Acta Pharmacol Sin, 2024, 45(5): 1019-1031.

[21]

Jiang W, Gan C, Zhou X, et al. Klotho inhibits renal ox-LDL deposition via IGF-1R/RAC1/OLR1 signaling to ameliorate podocyte injury in diabetic kidney disease[J].Cardiovasc Diabetol, 2023, 22(1): 293.

[22]

Zhang M, Gao X, Wu J, et al. Oxidized high-density lipoprotein enhances inflammatory activity in rat mesangial cells[J].Diabetes Metab Res Rev, 2010, 26: 455-463.

[23]

Kang HM, Ahn SH, Choi P, et al. Defective fatty acid oxidation in renal tubular epithelial cells has a key role in kidney fibrosis development[J].Nat Med, 2015, 21: 37-46.

[24]

Jiang WJ, Xu CT, Du CL, et al. Tubular epithelial cell-to-macrophage communication forms a negative feedback loop via extracellular vesicle transfer to promote renal inflammation and apoptosis in diabetic nephropathy[J].Theranostics, 2022, 12: 324-339.

[25]

Kostapanos MS, Florentin M, Elisaf MS.Fenofibrate and the kidney: an overview[J].Eur J Clin Invest, 2013, 43(5): 522-531.

[26]

Wilson PC, Wu H, Kirita Y, et al. The single-cell transcriptomic landscape of early human diabetic nephropathy[J].Proc Natl Acad Sci USA, 2019, 116: 19619-19625.

[27]

Kim Y, Park CW.Mechanisms of adiponectin action: implication of adiponectin receptor agonism in diabetic kidney disease[J].Int J Mol Sci, 2019, 20(7): 1782.

[28]

Zeng Y, Guo M, Wu Q, et al. Gut microbiota-derived indole-3-propionic acid alleviates diabetic kidney disease through its mitochondrial protective effect via reducing ubiquitination mediated-degradation of SIRT1[J].J Adv Res, 2025, 73: 607-630.

[29]

Zang N, Cui C, Guo X, et al. cGAS-STING activation contributes to podocyte injury in diabetic kidney disease[J].iScience, 2022, 25(10): 105145.

[30]

Liu X, Lu J, Liu S, et al. Huangqi-danshen decoction alleviates diabetic nephropathy in db/db mice by inhibiting PINK1/Parkin-mediated mitophagy[J].Am J Transl Res, 2020, 12(3):989-998.

[31]

Engelhart EA, Hoppins S. A catalytic domain variant of mitofusin requiring a wildtype paralog for function uncouples mitochondrial outer-membrane tethering and fusion[J].J Biol Chem, 2019, 294(20): 8001-8014.

[32]

Yang M, Zhang Q, Luo S, et al. DsbA-L alleviates tubular injury in diabetic nephropathy by activating mitophagy through maintenance of MAM integrity[J].Clin Sci (Lond), 2023, 137(12): 931-945.

[33]

Huang Q, Xiong X, Chen S, et al. Asprosin aggravates tubular epithelial cell injury and phenotypic transformation via mitochondrial dynamics disorder mediated by excessive Drp1 SUMOylation in diabetic nephropathy mice[J].Adv Sci (Weinh), 2025, 12(39): e03259.

[34]

Wan S, Wan S, Jiao X, et al. Advances in understanding the innate immune-associated diabetic kidney disease[J].FASEB J, 2021, 35(2): e21367.

[35]

Rayego-Mateos S, Rodrigues-Diez RR, Fernandez-Fernandez B, et al. Targeting inflammation to treat diabetic kidney disease: the road to 2030[J].Kidney Int, 2023, 103(2): 282-296.

[36]

Perez-Gomez MV, Sanchez-Niño MD, Sanz AB, et al. Targeting inflammation in diabetic kidney disease: early clinical trials[J].Expert Opin Investig Drugs, 2016, 25(9): 1045-1058.

[37]

Tuttle KR, Brosius FC, Adler SG, et al. JAK1/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a Phase 2 randomized controlled clinical trial[J].Nephrol Dial Transplant, 2018, 33(11): 1950-1959.

[38]

Motwani MP, Flint JD, De Maeyer RP, et al. Novel translational model of resolving inflammation triggered by UV-killed E. coli[J].J Pathol Clin Res, 2016, 2(3): 154-165.

[39]

Wu L, Liu C, Chang DY, et al. The attenuation of diabetic nephropathy by annexin a1 via regulation of lipid metabolism through the AMPK/PPARα/CPT1b pathway[J].Diabetes, 2021, 70(10): 2192-2203.

[40]

Li L, Tang W, Zhang Y, et al. Targeting tissue-resident memory CD8+ T cells in the kidney is a potential therapeutic strategy to ameliorate podocyte injury and glomerulosclerosis[J].Mol Ther, 2022, 30(8): 2746-2759.

[41]

Liu C, Qin L, Ding J, et al. Group 2 innate lymphoid cells participate in renal fibrosis in diabetic kidney disease partly via tgf-β1 signal pathway[J].J Diabetes Res, 2019, 2019: 8512028.

[42]

Eller K, Kirsch A, Wolf AM, et al. Potential role of regulatory T cells in reversing obesity-linked insulin resistance and diabetic nephropathy[J].Diabetes, 2011, 60(11): 2954-2962.

[43]

Pedigo CE, Ducasa GM, Leclercq F, et al. Local TNF causes NFATc1-dependent cholesterol-mediated podocyte injury[J].J Clin Invest, 2016, 126(9): 3336-3350.

[44]

Lee BT, Ahmed FA, Hamm LL, et al. Association of c-reactive protein, tumor necrosis factor-alpha, and interleukin-6 with chronic kidney disease[J].BMC Nephrol, 2015, 16: 77.

[45]

Wu R, Liu X, Yin J, et al. IL-6 receptor blockade ameliorates diabetic nephropathy via inhibiting inflammasome in mice[J].Metabolism, 2018, 83: 18-24.

[46]

Nørregaard R, Mutsaers HAM, Frøkiær J, et al. Obstructive nephropathy and molecular pathophysiology of renal interstitial fibrosis[J].Physiol Rev, 2023, 103(4): 2827-2872.

[47]

Xiao X, Ma B, Dong B, et al. Cellular and humoral immune responses in the early stages of diabetic nephropathy in NOD mice[J].J Autoimmun, 2009, 32(2): 85-93.

[48]

Imig JD, Ryan MJ. Immune and inflammatory role in renal disease[J].Compr Physiol, 2013, 3(2): 957-976.

[49]

Nicoloff G, Blazhev A, Petrova C,et al. Circulating immune complexes among diabetic children[J].Clin Dev Immunol, 2004, 11(1): 61-66.

[50]

Smith MJ, Simmons KM, Cambier JC.B cells in type 1 diabetes mellitus and diabetic kidney disease[J].Nat Rev Nephrol, 2017, 13: 712-720.

[51]

Kobori H, Ozawa Y, Suzaki Y, et al. Young scholars award lecture: intratubular angiotensinogen in hypertension and kidney diseases[J].Am J Hypertens, 2006, 19: 541-550.

[52]

Kim DL, Lee SE, Kim NH. Renal protection of mineralocorticoid receptor antagonist, finerenone, in diabetic kidney disease[J].Endocrinol Metab (Seoul), 2023, 38(1): 43-55.

[53]

Jia G, Lastra G, Bostick BP, et al. The mineralocorticoid receptor in diabetic kidney disease[J].Am J Physiol Renal Physiol, 2024, 327(3): F519-F531.

[54]

Hsu YH, Zheng CM, Chou CL, et al. Therapeutic effect of endothelin-converting enzyme inhibitor on chronic kidney disease through the inhibition of endoplasmic reticulum stress and the NLRP3 inflammasome[J].Biomedicines, 2021, 9(4): 398.

[55]

Xie H, Zhang X, Peng J, et al. Endothelin-1 down-regulated vascular endothelial growth factor A is involved in trichloroethene-induced kidney injury[J].Toxicol Ind Health, 2022, 38(5): 287-298.

[56]

Goddard J, Johnston NR, Hand MF, et al. Endothelin-A receptor antagonism reduces blood pressure and increases renal blood flow in hypertensive patients with chronic renal failure: a comparison of selective and combined endothelin receptor blockade[J].Circulation, 2004, 109(9): 1186-1193.

[57]

Hocher B, Schwarz A, Reinbacher D, et al. Effects of endothelin receptor antagonists on the progression of diabetic nephropathy[J].Nephron, 2001, 87(2): 161-169.

[58]

Mann JF, Green D, Jamerson K, et al. Avosentan for overt diabetic nephropathy[J].J Am Soc Nephrol, 2010, 21(3): 527-535.

[59]

Chang JH, Gurley SB.Assessment of diabetic nephropathy in the Akita mouse[J].Methods Mol Biol, 2012, 933: 17-29.

[60]

Wang W, Jiang S, Tang X, et al. Sex differences in progression of diabetic nephropathy in OVE26 type 1 diabetic mice[J].Biochim Biophys Acta Mol Basis Dis, 2020, 1866(1): 165589.

[61]

罗文婷, 唐诗韵, 肖湘, 等. DKD 动物模型的研究进展[J].成都医学院学报, 2023, 18(5): 650-657.

[62]

钱足平, 陈勇, 冉燕, 等. DKD 模型: 动物模型、二维细胞模拟及三维类器官模型[J].中国组织工程研究, 2025, 29(17): 3632-3640.

[63]

蒋子健, 陈钇地, 龙莉玲, 等. 扩散峰度成像早期诊断广西巴马小型猪 DKD 模型的价值[J].中华放射学杂志, 2019, 53(7): 609-614.

[64]

Gurley SB, Clare SE, Snow KP, et al. Impact of genetic background on nephropathy in diabetic mice[J].Am J Physiol Renal Physiol, 2006, 290(1): F214-222.

[65]

Wang Q, Hummler E, Nussberger J, et al. Blood pressure, cardiac, and renal responses to salt and deoxycorticosterone acetate in mice: role of renin genes[J].J Am Soc Nephrol, 2002, 13(6): 1509-1516.

[66]

Hu H, Hu J, Chen Z, et al. RBBP6-mediated ERRα degradation contributes to mitochondrial injury in renal tubular cells in diabetic kidney disease[J].Adv Sci (Weinh), 2024, 11(46): e2405153.

[67]

张翠香, 洪晓华, 侯金才, 等. 链脲佐菌素 DKD 大鼠模型肾小球损伤的机制[J].中华中医药杂志, 2015, 30(9): 3087-3091.

[68]

Harlan SM, Heinz-Taheny KM, Sullivan JM, et al. Progressive renal disease established by renin-coding adeno-associated virus-driven hypertension in diverse diabetic models[J].J Am Soc Nephrol, 2018, 29(2): 477-491.

[69]

Bossart M, Wagner M, Elvert R, et al. Effects on weight loss and glycemic control with SAR441255, a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist[J].Cell Metab, 2022, 34(1): 59-74. e10.

[70]

李沛城, 冯波. 《中国糖尿病防治指南 (2024 版)》更新要点解读[J].同济大学学报 (医学版), 2025, 46(2): 151-158.

[71]

中国中西医结合学会内分泌专业委员会. 渴络欣胶囊治疗糖尿病肾脏疾病临床应用专家共识[J].中国中西医结合杂志, 2020, 40(8): 979-984.

基金资助

湖南省自然科学基金(2024JJ8140)

湖南省重点研发计划(2023DK2006)

长沙市“小荷”青年人才创新项目(〔2022〕056)

国家自然科学基金(82173809)

国家自然科学基金(82470437)

AI Summary AI Mindmap
PDF (8133KB)

0

访问

0

被引

详细

导航
相关文章

AI思维导图

/

〈 〉